The UBS Upgrade on Lockheed Isn't About the F-35. It's About the Missiles.

On September 8, UBS moved Lockheed Martin from Neutral to Buy and raised its price target to $674 from $581. The stated reason mattered less than the number it dragged along: the bank called out "underappreciated missile growth." At a share price in the low $530s, the new target implied roughly 26% upside. The upgrade itself is one firm's opinion. What it points at is real and visible in the quarter Lockheed already reported.

The case for buying Lockheed has always been the F-35. It is the largest program in the portfolio, and for years the stock traded like a mature one: a giant, slow-growing contractor whose fate rises and falls with a single fighter jet and the Pentagon's budget knife. That is the mental model the consensus carries. The data now argues the stock has a second, faster engine nobody was pricing.

The quarter that already showed it

Lockheed's second-quarter results, reported July 23, look like a company outgrowing its reputation. Sales rose 11% to $20.1 billion. Diluted earnings came in at $7.94 a share. Free cash flow swung to $2.9 billion from a $150 million deficit a year earlier — the prior-year quarter was weighed down by $1.6 billion in program losses, a drag that did not repeat.

The headline that should have rewritten the story is the backlog. Lockheed ended June with a record $230.4 billion of contracted work, up from $193.6 billion at the end of 2025. Roughly two and a half years of revenue is already sold. Within that total sits the real signal. Missiles and Fire Control — the unit that makes interceptors, not jets — saw its backlog nearly double, to $87.9 billion, on the back of one contract in particular.

That segment was the quarter's best performer. Sales grew 19% to $4.1 billion, and operating profit rose 24%, lifting the unit's margin to 14.5% — materially richer than the corporate average. The drivers are the fast-moving munitions programs: PAC-3, Precision Strike Missiles, and THAAD. This is where the growth lives, and it is higher-margin growth than the F-35 franchise delivers.

The contract behind the re-rating

The centerpiece is the Terminal High Altitude Area Defense interceptor. In June, the Missile Defense Agency awarded Lockheed a seven-year procurement contract valued at $35.3 billion to quadruple THAAD interceptor production. It is one of the first multiyear acquisitions under the Pentagon's new buying strategy, which trades the old annual-budget whipsaw for predictable, contracted volume. THAAD is the only U.S. system built to intercept threats both inside and outside the atmosphere, and it has been combat-tested.

Three things make this contract structurally different from the F-35 story. It is a quantity ramp, not a single flagship — the point is to churn out many interceptors, not sell one expensive plane. It is multiyear and sole-source, giving Lockheed visibility it rarely had. And it was won at a moment when the scarcity argument became concrete: against cheap drones and missile barrages, the scarce resource is precisely a large supply of interceptors. When a technology makes the threat abundant, the defense against it becomes the scarce complement — and Lockheed is the only seller of this one.

That is what UBS was signaling. Applying a higher multiple than before reflects confidence that the growth is durable enough to deserve one, rather than a one-off earnings blip. The bank's $674 target sits well above the sell-side mean of roughly $636, so even the upgrade crowd disagrees on how much to pay. That gap is the debate the article really rests on.

What could break the story

The contract is real, but it is not yet a guaranteed flood of cash. It is an "undefinitized contract action" — the Pentagon awarded the ceiling, and final terms and pricing are still being negotiated. Lockheed acknowledged that funding, supply chains, and facility-buildout delays could trim it. The company is also spending heavily to expand capacity, including roughly $9 billion of investment through 2030, and management warned that near-term margin dilution comes with ramping production before contracts are fully finalized.

The deeper caveat is what the stock already reflects. On a forward basis Lockheed traded near 16 times earnings with a market value around $123 billion. That is not an obviously cheap number for a contractor. The bullish case now rests on a real, documented shift — missile and munitions volume accelerating at higher margins behind a contracted backlog — rather than on Lockheed being overlooked. Discovery is over; the question is whether the multiple moves up with the growth.

There is a version of this trade that works because the market is still anchored to the F-35, treating the missile business as an afterthought. The quarter and the contract say that anchor is stale. Whether $674 is the right number or not, the upgrade has identified the part of Lockheed that was actually growing. That is the part worth understanding, not the rating that drew attention to it.